Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research and Treatment
Published in: Breast Cancer Research and Treatment 2/1999

01-07-1999

Overexpression of basic fibroblast growth factor (FGF–2) downregulates Bcl–2 and promotes apoptosis in MCF–7 human breast cancer cells

Authors: Paul Maloof, Qin Wang, Huisheng Wang, Dana Stein, Thomas N. Denny, Joachim Yahalom, Eyal Fenig, Robert Wieder

Published in: Breast Cancer Research and Treatment | Issue 2/1999

Login to get access
Metadata
Title
Overexpression of basic fibroblast growth factor (FGF–2) downregulates Bcl–2 and promotes apoptosis in MCF–7 human breast cancer cells
Authors
Paul Maloof
Qin Wang
Huisheng Wang
Dana Stein
Thomas N. Denny
Joachim Yahalom
Eyal Fenig
Robert Wieder
Publication date
01-07-1999
Publisher
Kluwer Academic Publishers
Published in
Breast Cancer Research and Treatment / Issue 2/1999
Print ISSN: 0167-6806
Electronic ISSN: 1573-7217
DOI
https://doi.org/10.1023/A:1006258510381

Other articles of this Issue 2/1999

Breast Cancer Research and Treatment 2/1999 Go to the issue

OriginalPaper

Meta‐analysis of trials comparing toremifene with tamoxifen and factors predicting outcome of antiestrogen therapy in postmenopausal women with breast cancer

OriginalPaper

Three new active cisplatin‐containing combinations in the neoadjuvant treatment of locally advanced and locally recurrent breast carcinoma: a randomized phase II trial

OriginalPaper

Hsp27 overexpression inhibits doxorubicin–induced apoptosis in human breast cancer cells

OriginalPaper

Expression of inducible nitric oxide synthase in human breast cancer depends on tumor grade

OriginalPaper

PACAP (6–38) is a PACAP receptor antagonist for breast cancer cells

OriginalPaper

G1‐S transition defects occur in most breast cancers and predict outcome
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits